Human papillomavirus type 16 L1 capsid protein antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Cervarix, Gardasil, Gardasil 9
Generic Name
Human papillomavirus type 16 L1 capsid protein antigen
DrugBank Accession Number
DB10301
Background

Human papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • L1 protein, Human papillomavirus type 16 Vaccine
  • Recombinant human papillomavirus type 16 L1 protein

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
CervarixHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg/0.5ml) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg/0.5ml)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
CervarixHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg/0.5ml) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg/0.5ml)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
CERVARIXHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg/0.5ml) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg/0.5ml)InjectionIntramuscularบริษัท แกล็กโซสมิทไคล์น (ประเทศไทย) จำกัด2011-08-18Not applicableThailand flag
CervarixHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg/0.5ml) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg/0.5ml)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
CervarixHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg / 0.5 mL) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg / 0.5 mL)SuspensionIntramuscularGlaxosmithkline Inc2010-02-10Not applicableCanada flag
CervarixHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg/0.5ml) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg/0.5ml)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
CervarixHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg/0.5ml) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg/0.5ml)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
CervarixHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg/0.5ml) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg/0.5ml)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
CervarixHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg/0.5ml) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg/0.5ml)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
CervarixHuman papillomavirus type 16 L1 capsid protein antigen (20 mcg/0.5ml) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg/0.5ml)Injection, suspensionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
6LTE2DNX63
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910487
RxNav
798264

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionAllogeneic Hematopoietic Stem Cell Transplant Recipient / Hematopoietic and Lymphoid Cell Neoplasm1
4Active Not RecruitingPreventionCervical Cancers / Cervical Precancerous Lesions1
4Active Not RecruitingPreventionHuman Papillomavirus Infections / Human Papillomavirus-Related Cervical Carcinoma1
4Active Not RecruitingPreventionPapillomavirus Infections1
4CompletedHealth Services ResearchCervical Intraepithelial Neoplasia (CIN) / HPV-Related Cervical Carcinoma1
4CompletedOtherCervical Cancers / Hpv / Warts1
4CompletedOtherHealthy Volunteers1
4CompletedPreventionAdenocarcinoma in Situ / Cervical Cancers / Cervical Intraepithelial Neoplasia (CIN)1
4CompletedPreventionAIN / Human Immunodeficiency Virus (HIV) Infections1
4CompletedPreventionCervical Cancers3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntramuscular
SuspensionIntramuscular
Injection, suspensionIntramuscular
Injection, suspensionIntramuscular; Parenteral
Injection, solutionIntramuscular
Injection
Injection, suspension
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:03 / Updated on February 13, 2021 10:52